{ "as_of": "2026-07-21T23:25:53.548259", "condition": "Knowledge-only: claude-haiku-4-5 answering with NO documents (parametric knowledge), graded by each harness's own judge", "harness": "test_portmem_vs_llm", "n": 100, "knowledge_only": { "currency_correct": 0.29 }, "wall_s": 42.3, "rows": [ { "pair_id": "fda_0000", "track_b": { "text": "I cannot provide a specific answer without knowing which drug you're referring to. Please specify the drug name and condition, and I can tell you its current FDA approval status and any regulatory actions that may have affected it.", "input_tokens": 96, "output_tokens": 46 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n- **currency_correct=0**: The answer does not mention the recall/enfor" } }, { "pair_id": "fda_0001", "track_b": { "text": "# Nasal Decongestants for Congestion Relief\n\n**Pseudoephedrine** (Sudafed) and **phenylephrine** remain FDA-approved for temporary relief of nasal congestion from colds, allergies, and sinus pressure. However, **phenylephrine's oral form** (in many OTC products) has faced scrutiny\u2014the FDA requested manufacturers remove it from oral products in 2023 due to insufficient evidence of effectiveness, though some products remain on shelves during the transition period. **Pseudoephedrine is still considered safe and effective** for this indication and remains widely available, though it requires ID verification at purchase due to methamphetamine precursor concerns.", "input_tokens": 111, "output_tokens": 158 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\nThe question asks about **oxymetazoline**, but the answer discusses *" } }, { "pair_id": "fda_0002", "track_b": { "text": "# FDA Status: HIV Protease Inhibitors\n\nBased on your description, you're asking about **protease inhibitors for HIV treatment**. Several protease inhibitors remain FDA-approved and safe for HIV-1 treatment when combined with other antiretrovirals, including **ritonavir-boosted** formulations like darunavir/ritonavir and atazanavir/ritonavir.\n\nHowever, **some older protease inhibitors have been withdrawn or are no longer recommended** (e.g., lopinavir/ritonavir is rarely used now due to better alternatives). Current guidelines prefer newer integrase inhibitors and other drug classes as first-line therapy, though protease inhibitors remain viable options.\n\nTo give you a definitive answer about a *specific* protease inhibitor, please name the drug.", "input_tokens": 123, "output_tokens": 186 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not mention nelfinavir spec" } }, { "pair_id": "fda_0003", "track_b": { "text": "# Edarbyclor Status\n\n**Edarbyclor remains currently approved and safe** for the treatment of hypertension. It is an FDA-approved combination medication containing azilsartan medoxomil and chlorthalidone, indicated for patients whose blood pressure is not adequately controlled on monotherapy. There have been no FDA regulatory actions withdrawing or significantly restricting its approval.", "input_tokens": 127, "output_tokens": 87 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer states \"Edarbyclor remains curre" } }, { "pair_id": "fda_0004", "track_b": { "text": "# Low Molecular Weight Heparin (LMWH) Status\n\nLMWHs remain **currently approved and safe** for DVT prophylaxis in abdominal surgery, hip replacement, and knee replacement surgery. Common agents like enoxaparin (Lovenox) and dalteparin (Fragmin) retain their FDA approvals for these indications with no major regulatory action withdrawing or restricting these uses.\n\nStandard dosing and monitoring practices continue as established, though prescribers should remain aware of contraindications (e.g., heparin-induced thrombocytopenia history) and renal dosing considerations.", "input_tokens": 134, "output_tokens": 145 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer states that enoxaparin \"remains " } }, { "pair_id": "fda_0005", "track_b": { "text": "I'd be happy to help, but your question appears incomplete. You've described a drug indicated for duodenal ulcer treatment for up to 8 weeks (typically healing within 4 weeks), but you haven't specified which drug you're asking about.\n\nCould you please provide the drug name? Once you do, I can tell you whether it remains FDA-approved and safe, and what its current maintenance therapy indications are.", "input_tokens": 126, "output_tokens": 93 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not mention the FDA recall " } }, { "pair_id": "fda_0006", "track_b": { "text": "I cannot provide a specific answer without knowing which drug you're referring to. Please specify the drug name and condition, and I can tell you its current FDA approval status and any regulatory actions that may have affected it.", "input_tokens": 96, "output_tokens": 46 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not address the specific dr" } }, { "pair_id": "fda_0007", "track_b": { "text": "# Fluphenazine Hydrochloride Elixir Status\n\nFluphenazine hydrochloride elixir **remains FDA-approved** for managing psychotic disorders. However, the FDA has not established efficacy for managing **behavioral complications of dementia** in elderly patients\u2014this indication was never approved and carries a black box warning for increased mortality risk in this population.\n\nThe drug's approval status for its labeled psychiatric indications has not been withdrawn, though it is now considered a first-generation antipsychotic with a less favorable safety profile compared to newer agents.", "input_tokens": 127, "output_tokens": 128 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n1. **currency_correct=0**: The answer states the drug \"remains FDA-ap" } }, { "pair_id": "fda_0008", "track_b": { "text": "I don't have specific information about a product line called \"Acne Clearing Cleanser/Tonic/Treatment 101\" in my knowledge base. To determine current FDA status, I'd recommend:\n\n1. Checking the FDA's official database (Drugs@FDA or searching by product name)\n2. Contacting the manufacturer directly for current approval status\n3. Consulting the product's label for active ingredients and any FDA warnings\n\nIf you can provide the active ingredient(s) or manufacturer name, I may be able to give more specific guidance.", "input_tokens": 110, "output_tokens": 122 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not mention any recall or e" } }, { "pair_id": "fda_0009", "track_b": { "text": "I cannot provide a specific answer without knowing which drug you're referring to. Please specify the drug name and condition, and I can tell you its current FDA approval status and any regulatory actions that may have affected it.", "input_tokens": 96, "output_tokens": 46 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not address the specific dr" } }, { "pair_id": "fda_0010", "track_b": { "text": "# Interleukin-23 Antagonist Status\n\nBased on your description, you're referring to **risankizumab** (Skyrizi), an IL-23 antagonist approved for moderate-to-severe plaque psoriasis in adults and pediatric patients \u22656 years weighing \u226540 kg.\n\n**Current Status:** This drug remains **FDA-approved and safe** for this indication. There have been no FDA regulatory actions withdrawing or significantly restricting this approval. Risankizumab continues to be actively marketed and used for psoriasis treatment.\n\n(Note: Your question appears cut off\u2014if you meant a different indication or drug, please clarify for a more specific answer.)", "input_tokens": 134, "output_tokens": 161 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\nThe answer discusses **risankizumab (Skyrizi)**, not **guselkumab" } }, { "pair_id": "fda_0011", "track_b": { "text": "# FDA Status Answer\n\nBased on your description, you're likely referring to **opioid analgesics** (such as morphine, oxycodone, or similar formulations). These remain **FDA-approved and currently indicated for acute severe pain** in adults and pediatric patients \u226550 kg.\n\nHowever, the FDA has significantly **strengthened safety warnings and restrictions** on opioids since 2016, including mandatory Risk Evaluation and Mitigation Strategies (REMS), black box warnings about addiction/overdose risk, and recommendations for non-opioid alternatives when possible. The indication itself hasn't been withdrawn, but prescribing practices are now more cautious.\n\n**To give you a definitive answer, please specify the exact drug name**, as regulatory status varies by specific opioid formulation.", "input_tokens": 125, "output_tokens": 179 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer states morphine remains \"FDA-app" } }, { "pair_id": "fda_0012", "track_b": { "text": "# Buprenorphine Sublingual Tablet Status\n\nBuprenorphine sublingual tablets remain **currently approved and safe** by the FDA for opioid dependence treatment and are indeed preferred for induction therapy.\n\nThe drug should be used as part of a **complete treatment program** that includes counseling and psychosocial support. There has been no FDA regulatory action withdrawing or changing its approved status\u2014it remains a first-line medication for opioid use disorder.", "input_tokens": 122, "output_tokens": 107 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly states that buprenorph" } }, { "pair_id": "fda_0013", "track_b": { "text": "# FDA Status of Fluoroquinolone Antibiotics\n\nBased on your question about antibacterial drug resistance, you're asking about **fluoroquinolones** (like ciprofloxacin, levofloxacin). These drugs remain **FDA-approved and currently available**, but their approved indications have been **significantly restricted** due to safety concerns.\n\nIn 2016 and subsequent years, the FDA issued warnings limiting fluoroquinolone use to serious infections where benefits outweigh risks (such as anthrax, plague, and certain resistant infections), moving away from routine use for common infections like uncomplicated urinary tract infections and sinusitis. The drugs are still safe when used appropriately for their current approved indications, but regulatory action has substantially narrowed their approved uses.", "input_tokens": 117, "output_tokens": 174 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n1. **currency_correct=0**: The answer discusses fluoroquinolones (cip" } }, { "pair_id": "fda_0014", "track_b": { "text": "# Ondansetron (Zofran)\n\nYes, ondansetron tablets remain **currently FDA-approved and safe** for prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin \u226550 mg/m\u00b2. This indication has not been withdrawn or superseded by regulatory action.\n\nThe drug continues to be a standard antiemetic agent in oncology practice with an established safety profile, though prescribing information may have been updated over time with additional safety data or warnings.", "input_tokens": 124, "output_tokens": 118 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly states that ondansetro" } }, { "pair_id": "fda_0015", "track_b": { "text": "I cannot provide a specific answer without knowing which drug you're referring to. Please specify the drug name and condition, and I can tell you its current FDA approval status and any regulatory actions that may have affected it.", "input_tokens": 96, "output_tokens": 46 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not address the specific dr" } }, { "pair_id": "fda_0016", "track_b": { "text": "# Cathflo\u00ae Activase\u00ae (alteplase) - Current Status\n\n**Yes, Cathflo\u00ae Activase\u00ae remains FDA-approved and currently marketed** for restoring function to central venous access devices (CVADs). The drug has maintained its approval since it was first approved in 2001 for this specific indication.\n\nThere have been no FDA regulatory actions withdrawing or significantly restricting this approval. It continues to be used clinically for catheter clearance when blood clots obstruct central lines.", "input_tokens": 119, "output_tokens": 116 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer states \"There have been no FDA r" } }, { "pair_id": "fda_0017", "track_b": { "text": "# FDA Status of Androgens for Primary Hypogonadism\n\n**Current Status: Still Approved**\n\nAndrogens (testosterone replacement therapy) remain FDA-approved for treating primary hypogonadism in males, including both congenital and acquired forms. This indication has not been withdrawn or superseded.\n\n**Important Safety Note:** However, the FDA has strengthened warnings over the past decade regarding cardiovascular risks, thromboembolic events, and polycythemia with testosterone therapy, particularly in older men and those with existing cardiovascular disease. Prescribers must now carefully evaluate risks versus benefits and monitor patients appropriately.", "input_tokens": 123, "output_tokens": 138 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly acknowledges that test" } }, { "pair_id": "fda_0018", "track_b": { "text": "# Answer\n\nBased on your description, you're referring to **aspirin**, which remains **FDA-approved and safe** for this indication (secondary prevention of cardiovascular events). However, the indication for **primary prevention** (reducing first cardiovascular events in asymptomatic people) has been significantly restricted in recent years due to FDA warnings about bleeding risk outweighing benefits in low-risk populations.\n\nThe FDA's stance has evolved to recommend aspirin primarily for **secondary prevention** (after a prior heart attack or stroke) rather than routine primary prevention, though some use in primary prevention may still be considered in select high-risk patients.", "input_tokens": 126, "output_tokens": 135 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\nThe answer is about **aspirin**, not **simvastatin**. This is a funda" } }, { "pair_id": "fda_0019", "track_b": { "text": "I cannot provide a specific answer without knowing which drug you're referring to. Please specify the drug name and condition, and I can tell you its current FDA approval status and any regulatory actions that may have affected it.", "input_tokens": 96, "output_tokens": 46 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not mention the recall/enfo" } }, { "pair_id": "fda_0020", "track_b": { "text": "# FDA Status: Antihistamines for Allergy Symptoms\n\nYes, antihistamines are still currently approved and safe for these symptoms. Over-the-counter antihistamines like **cetirizine (Zyrtec), loratadine (Claritin), and fexofenadine (Allegra)** remain FDA-approved for allergic rhinitis symptoms including runny nose, sneezing, and itchy/watery eyes.\n\nThere have been no major FDA regulatory actions withdrawing approval for these medications, though the agency continues to monitor safety and has issued guidance on proper use and labeling over the years.", "input_tokens": 119, "output_tokens": 144 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly states that cetirizine" } }, { "pair_id": "fda_0021", "track_b": { "text": "# Dorzolamide/Timolol Ophthalmic Solution Status\n\n**Currently approved and safe.** Dorzolamide hydrochloride and timolol maleate ophthalmic solution remains FDA-approved for reducing elevated intraocular pressure in open-angle glaucoma and ocular hypertension. There have been no major FDA regulatory actions withdrawing or significantly restricting this combination therapy, which continues to be a standard treatment option.", "input_tokens": 131, "output_tokens": 103 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly states that dorzolamid" } }, { "pair_id": "fda_0022", "track_b": { "text": "# Iclevia (Levonorgestrel/Ethinyl Estradiol) Status\n\n**Iclevia remains FDA-approved and currently marketed** for contraception in females of reproductive potential. There have been no FDA withdrawals, recalls, or safety actions that have removed it from the market.\n\nIclevia is a standard combined oral contraceptive (COC) containing levonorgestrel and ethinyl estradiol, and continues to be used as indicated for pregnancy prevention with the typical safety profile associated with hormonal contraceptives.", "input_tokens": 131, "output_tokens": 124 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\nThe question asks about \"estradiol\" as a drug, but the answer discuss" } }, { "pair_id": "fda_0023", "track_b": { "text": "# Acetaminophen (Tylenol) Status\n\n**Yes, acetaminophen remains FDA-approved and safe** for the uses you listed (headache, cold symptoms, backache, arthritis pain, toothache, muscle aches, and menstrual cramps) when used as directed.\n\nHowever, the FDA has strengthened safety warnings over the years, particularly regarding:\n- **Liver toxicity risk** at high doses or with chronic use\n- **Combination products** (many OTC cold/flu medicines contain acetaminophen, risking accidental overdose)\n\nCurrent labeling emphasizes not exceeding 3,000-4,000 mg daily and avoiding concurrent use with alcohol or other acetaminophen-containing products.", "input_tokens": 127, "output_tokens": 167 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly identifies that acetam" } }, { "pair_id": "fda_0024", "track_b": { "text": "# Pregabalin (Lyrica) Status\n\n**Yes, pregabalin capsules remain FDA-approved and safe for both indications you mentioned:**\n\n1. **Postherpetic neuralgia (PHN)** - approved since 2004\n2. **Adjunctive therapy for partial onset seizures** - approved since 2004\n\nThere have been no FDA withdrawals or major regulatory actions removing these approvals. The drug continues to be widely prescribed for these indications, though it carries standard warnings about dizziness, somnolence, and potential for dependence/abuse (Schedule V controlled substance).", "input_tokens": 127, "output_tokens": 139 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly states that pregabalin" } }, { "pair_id": "fda_0025", "track_b": { "text": "# Azacitidine for MDS\n\n**Yes, azacitidine (Vidaza) remains FDA-approved and currently indicated for myelodysplastic syndrome (MDS).** It is approved for adult patients with MDS, including refractory anemia and other FAB subtypes, and continues to be considered a standard treatment option. No FDA regulatory action has withdrawn or significantly altered its approval status for this indication.", "input_tokens": 129, "output_tokens": 96 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly states that azacitidin" } }, { "pair_id": "fda_0026", "track_b": { "text": "# FDA Status: Sertraline (Zoloft)\n\nBased on your description, this appears to be **sertraline (Zoloft)**, which remains **currently approved and safe** by the FDA for both major depressive disorder and obsessive-compulsive disorder (OCD).\n\nThere have been no FDA regulatory actions withdrawing or significantly restricting these indications. Sertraline continues to be widely prescribed as a first-line SSRI antidepressant with an established safety profile, though like all SSRIs it carries standard warnings (e.g., black box warning for increased suicidal thoughts in young adults).", "input_tokens": 125, "output_tokens": 141 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer discusses sertraline (Zoloft), n" } }, { "pair_id": "fda_0027", "track_b": { "text": "# FDA Status for These Indications\n\n**Dermatitis Herpetiformis (D.H.):** Dapsone remains FDA-approved and is the standard first-line treatment for this condition.\n\n**Leprosy:** Dapsone is still FDA-approved for leprosy treatment in all forms except those with proven dapsone resistance, exactly as you've stated. It remains a WHO-recommended component of multidrug therapy for leprosy.\n\nBoth indications retain their approved status with no FDA regulatory action withdrawing or restricting these uses.", "input_tokens": 117, "output_tokens": 126 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly states that dapsone re" } }, { "pair_id": "fda_0028", "track_b": { "text": "# Sertraline (Zoloft) Status\n\nBased on your description, this is **sertraline**, an SSRI antidepressant. It remains **currently FDA-approved and safe** for all the indications you listed (MDD, OCD, PD, and social anxiety disorder) in adults.\n\nThere have been no FDA regulatory actions withdrawing or significantly restricting sertraline's approval for these conditions. It continues to be widely prescribed with standard safety monitoring for SSRIs (including black box warning for increased suicidal thoughts in young adults).", "input_tokens": 128, "output_tokens": 125 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n- The answer is about **sertraline (Zoloft)**, not **paroxetine**" } }, { "pair_id": "fda_0029", "track_b": { "text": "I cannot provide a specific answer without knowing which drug you're referring to. Please specify the drug name and condition, and I can tell you its current FDA approval status and any regulatory actions that may have affected it.", "input_tokens": 96, "output_tokens": 46 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer fails to address the specific dr" } }, { "pair_id": "fda_0030", "track_b": { "text": "# Albuterol HFA (Beta-2 Agonist)\n\n**Current Status: APPROVED and SAFE**\n\nAlbuterol HFA (hydrofluoroalkane) inhalers remain FDA-approved for treatment and prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease. No major FDA regulatory action has withdrawn or significantly altered this approval. It remains a first-line rescue medication for asthma and COPD.", "input_tokens": 133, "output_tokens": 114 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly states that albuterol " } }, { "pair_id": "fda_0031", "track_b": { "text": "# Parenteral Diazepam Status\n\nParenteral diazepam injection remains **currently FDA-approved and safe** for the indications you mentioned: treatment of generalized tonic-clonic status epilepticus and prevention/treatment of seizures during neurosurgery.\n\nHowever, **lorazepam** has become the preferred first-line benzodiazepine for acute seizure management and status epilepticus due to superior pharmacokinetics (longer duration of action), though diazepam remains an acceptable alternative when lorazepam is unavailable.", "input_tokens": 123, "output_tokens": 127 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly identifies that parent" } }, { "pair_id": "fda_0032", "track_b": { "text": "# Dextran 6% in 0.9% Sodium Chloride\n\nThis product **remains FDA-approved** for the indicated use of treating hypovolemia when plasma volume expansion is desired.\n\nHowever, **clinical use has significantly declined** due to safety concerns identified over decades, including increased risk of acute kidney injury, anaphylaxis, and coagulopathy. While not formally withdrawn, major medical guidelines and institutions have largely moved away from dextran in favor of safer alternatives (crystalloids, albumin, or other colloids). The FDA has not issued a formal recall, but the drug's role in modern practice is substantially limited compared to its historical use.", "input_tokens": 129, "output_tokens": 146 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer states the product \"remains FDA-" } }, { "pair_id": "fda_0033", "track_b": { "text": "# CGRP Receptor Antagonist Status\n\nBased on your description, you're referring to **erenumab (Aimovig)** or another monoclonal antibody CGRP antagonist like **fremanezumab (Ajovy)** or **galcanezumab (Emgality)**.\n\nThese drugs **remain FDA-approved and currently safe** for both acute and preventive migraine treatment in adults. There have been no FDA withdrawals or major safety-based regulatory actions that have changed their approved status, though ongoing pharmacovigilance continues as with all medications.\n\n*Note: Your question appears incomplete regarding the preventive indication\u2014if you can provide the full indication, I can give more specific information.*", "input_tokens": 129, "output_tokens": 163 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer states these drugs \"remain FDA-a" } }, { "pair_id": "fda_0034", "track_b": { "text": "I cannot provide a specific answer without knowing which drug you're referring to. Please specify the drug name and condition, and I can tell you its current FDA approval status and any regulatory actions that may have affected it.", "input_tokens": 96, "output_tokens": 46 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not address the actual FDA " } }, { "pair_id": "fda_0035", "track_b": { "text": "# Lorazepam for Anxiety - Current FDA Status\n\nLorazepam remains **FDA-approved and currently indicated** for anxiety disorders and short-term anxiety relief. However, the FDA has issued important safety warnings: benzodiazepines like lorazepam carry black box warnings regarding risks of dependence, abuse, respiratory depression, and serious adverse effects when combined with opioids. Current prescribing guidance emphasizes using the lowest effective dose for the shortest duration possible due to these safety concerns.", "input_tokens": 120, "output_tokens": 111 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n1. **currency_correct=0**: The answer discusses lorazepam (a benzodia" } }, { "pair_id": "fda_0036", "track_b": { "text": "# Ofloxacin Ophthalmic Solution Status\n\nOfloxacin ophthalmic solution remains **currently FDA-approved and available** for treating bacterial eye infections caused by susceptible organisms. It is still considered safe when used as directed for conditions like bacterial conjunctivitis and corneal ulcers.\n\nHowever, fluoroquinolone ophthalmic agents (including ofloxacin) have faced increased scrutiny regarding rare but serious adverse effects, and some formulations have been withdrawn from certain markets. The FDA has not withdrawn ofloxacin ophthalmic solution, but prescribers should be aware of current labeling regarding potential risks and ensure appropriate use in indicated conditions.", "input_tokens": 117, "output_tokens": 155 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n1. **currency_correct=0**: The answer discusses ofloxacin ophthalmic " } }, { "pair_id": "fda_0037", "track_b": { "text": "# FDA Status of ARBs for Hypertension\n\nARBs (angiotensin II receptor blockers) remain **currently approved and safe** for treating hypertension in adults and children \u22651 year of age. There has been no FDA withdrawal or major regulatory action changing this indication.\n\nHowever, note that **ARBs are NOT approved for heart failure treatment in children**\u2014this indication is limited to adults. If you're asking about a specific ARB product, please clarify the drug name for precise status confirmation.", "input_tokens": 136, "output_tokens": 117 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer states ARBs \"remain currently ap" } }, { "pair_id": "fda_0038", "track_b": { "text": "I cannot provide a specific answer without knowing which drug you're referring to. Please specify the drug name and condition, and I can tell you its current FDA approval status and any regulatory actions that may have affected it.", "input_tokens": 96, "output_tokens": 46 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n- **currency_correct=0**: The answer does not address the specific dru" } }, { "pair_id": "fda_0039", "track_b": { "text": "# FDA Status Answer\n\nBased on the indication you've described (symptomatic relief of anxiety and tension associated with psychoneurosis), this appears to reference **benzodiazepines**, likely **meprobamate** or a similar anxiolytic from that era.\n\n**Current Status:** These drugs remain FDA-approved for anxiety, but the indications and labeling have been significantly updated. The term \"psychoneurosis\" is outdated psychiatric terminology no longer used in modern FDA labeling. Current approvals specify anxiety disorders with more precise diagnostic criteria (generalized anxiety disorder, panic disorder, etc.).\n\n**Regulatory Changes:** The FDA has strengthened warnings about dependence, abuse potential, and CNS depression risks, particularly regarding concurrent opioid use. Benzodiazepines now carry black box warnings for these risks.\n\nCould you provide the complete drug name or indication? That would allow a more precise answer about that specific agent's current approval status.", "input_tokens": 122, "output_tokens": 206 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\nThe answer fails on both metrics:\n\n1. **currency_correct=0**: The ans" } }, { "pair_id": "fda_0040", "track_b": { "text": "# Naproxen Approval Status\n\nNaproxen tablets and naproxen sodium tablets **remain currently FDA-approved** for the relief of signs and symptoms of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. However, the indication appears incomplete in your question (ending with \"Polya?\"), so I cannot confirm the full list.\n\n**Important safety note:** The FDA has strengthened warnings about cardiovascular and gastrointestinal risks with NSAIDs like naproxen, particularly with long-term use, but the drug has not been withdrawn or had its core approvals revoked.", "input_tokens": 137, "output_tokens": 145 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n1. **currency_correct=0**: The answer states the drug \"remain current" } }, { "pair_id": "fda_0041", "track_b": { "text": "# Voriconazole Status\n\n**Voriconazole** (an azole antifungal) remains **currently FDA-approved and safe** for prophylaxis of invasive Aspergillus and Candida infections in high-risk patients. There has been no FDA withdrawal or major regulatory action changing its approved status for this indication.\n\nHowever, note that in 2022, the FDA added a **black box warning** regarding hepatotoxicity and the risk of serious hepatic injury, requiring monitoring of liver function tests during treatment.", "input_tokens": 129, "output_tokens": 121 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n1. **currency_correct=0**: The answer discusses voriconazole (not pos" } }, { "pair_id": "fda_0042", "track_b": { "text": "I cannot provide a specific answer without knowing which drug you're referring to. Please specify the drug name and condition, and I can tell you its current FDA approval status and any regulatory actions that may have affected it.", "input_tokens": 96, "output_tokens": 46 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not mention the recall/enfo" } }, { "pair_id": "fda_0043", "track_b": { "text": "# MAXALT (rizatriptan) - Current FDA Status\n\n**MAXALT and MAXALT-MLT remain currently approved by the FDA** for acute migraine treatment in adults and pediatric patients 6-17 years old. No FDA regulatory action has withdrawn or significantly altered this indication.\n\nThe drug continues to be marketed with its established safety profile, though like all triptans, it carries standard warnings regarding cardiovascular risks and serotonin syndrome. The indication you cited remains valid as of current FDA records.", "input_tokens": 138, "output_tokens": 114 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly states that MAXALT (ri" } }, { "pair_id": "fda_0044", "track_b": { "text": "# Antihistamines for Allergic Conditions\n\nBased on your question about antihistamines (the text appears to reference first-generation antihistamines like diphenhydramine or similar agents) for allergic rhinitis, conjunctivitis, and mild allergic skin manifestations:\n\n**These indications remain FDA-approved and safe** when used as directed. However, **second-generation antihistamines (cetirizine, loratadine, fexofenadine)** are now preferred over first-generation agents due to better safety profiles with fewer anticholinergic and sedating side effects.\n\nFirst-generation antihistamines carry FDA warnings about drowsiness and impaired cognition, making them less ideal for routine use, though they remain approved for these conditions.", "input_tokens": 133, "output_tokens": 176 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\nThe answer discusses promethazine (a first-generation antihistamine) " } }, { "pair_id": "fda_0045", "track_b": { "text": "# FDA Status: Nitrates for Angina\n\n**Current Status: Still Approved and Safe**\n\nNitrates (long-acting formulations like isosorbide dinitrate and isosorbide mononitrate tablets) remain FDA-approved for treating angina, including vasospastic (Prinzmetal's) and unstable angina. No FDA regulatory action has withdrawn or significantly altered their approval for these indications.\n\n**Note:** Standard practice now emphasizes nitrate-free intervals (10-14 hours daily) to prevent tolerance development, which represents an evolution in safe use rather than a change in approval status.", "input_tokens": 137, "output_tokens": 138 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly states \"No FDA regulat" } }, { "pair_id": "fda_0046", "track_b": { "text": "# FDA Status: Ceftriaxone Injection, USP\n\n**Current Status: Still Approved and Safe**\n\nCeftriaxone injection remains FDA-approved for treating respiratory tract infections caused by *Streptococcus pneumoniae* and *Klebsiella* species. There has been no FDA regulatory action withdrawing or significantly restricting this indication.\n\nThe drug continues to be widely used clinically with standard safety monitoring for known adverse effects (e.g., allergic reactions, C. difficile infection).", "input_tokens": 126, "output_tokens": 118 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer states \"Still Approved and Safe\"" } }, { "pair_id": "fda_0047", "track_b": { "text": "I cannot provide a specific answer without knowing which drug you're referring to. Please specify the drug name and condition, and I can tell you its current FDA approval status and any regulatory actions that may have affected it.", "input_tokens": 96, "output_tokens": 46 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not address whether the dru" } }, { "pair_id": "fda_0048", "track_b": { "text": "# Capecitabine (Xeloda) - Current Status\n\n**Capecitabine remains FDA-approved and safe** for adjuvant treatment of Stage III colon cancer. It is indicated both as monotherapy and in combination regimens (particularly with oxaliplatin as part of XELOX/CAPOX).\n\nThere have been no FDA withdrawals or safety-based regulatory actions that have changed its approved status for this indication since its original approval. It continues to be a standard treatment option in colorectal cancer care.", "input_tokens": 127, "output_tokens": 120 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly states that capecitabi" } }, { "pair_id": "fda_0049", "track_b": { "text": "# FDA Status: Amphetamine Extended-Release (ADHD)\n\nWithout the specific drug name, I cannot provide a definitive answer. However, amphetamine hydrochloride extended-release capsules for pediatric ADHD (ages 6-12) remain **FDA-approved and currently safe** when used as directed.\n\n**Key point:** If this refers to a specific branded formulation, verify the current status on FDA.gov or consult the package insert, as individual products may have had labeling changes, manufacturing updates, or market withdrawals unrelated to safety concerns.", "input_tokens": 132, "output_tokens": 128 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer states the drug \"remain[s] FDA-a" } }, { "pair_id": "fda_0050", "track_b": { "text": "# FDA Status of Fluoroquinolone Antibiotics\n\nThe drug class you're referring to appears to be **fluoroquinolones** (like ciprofloxacin, levofloxacin). These remain **FDA-approved and currently used**, but their approved indications have been **significantly restricted** due to safety concerns.\n\nIn 2016 and subsequent years, the FDA issued warnings limiting fluoroquinolones to serious infections where benefits outweigh risks, due to associations with tendon rupture, peripheral neuropathy, and CNS effects. They are no longer recommended for uncomplicated infections like simple UTIs or bronchitis.\n\nThe drugs are still safe and appropriate for serious bacterial infections (like complicated UTIs, pneumonia, and anthrax), but regulatory action has narrowed their use considerably.", "input_tokens": 117, "output_tokens": 180 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n1. **currency_correct=0**: The answer discusses fluoroquinolones (cip" } }, { "pair_id": "fda_0051", "track_b": { "text": "# FDA Status: Topical Antibiotic Ointments for Minor Wounds\n\nYes, topical antibiotic ointments (such as those containing bacitracin, neomycin, and polymyxin B) remain **currently approved and safe** by the FDA for first aid use on minor cuts, scrapes, and burns to help prevent infection.\n\nHowever, the FDA has issued warnings about **neomycin** specifically, noting increased reports of allergic contact dermatitis. Products containing only bacitracin and polymyxin B (without neomycin) are generally preferred to minimize this risk.", "input_tokens": 96, "output_tokens": 139 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer discusses topical antibiotic oin" } }, { "pair_id": "fda_0052", "track_b": { "text": "I'd be happy to help, but I need you to specify which drug you're asking about. Your question contains a placeholder (\"this drug\") rather than an actual drug name, and the indication text appears cut off at \"inad[equate].\"\n\nPlease provide:\n1. The specific drug name (e.g., morphine, oxycodone, etc.)\n2. The complete indication if possible\n\nOnce you clarify, I can tell you about its current FDA approval status and any regulatory actions.", "input_tokens": 120, "output_tokens": 110 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not address hydromorphone's" } }, { "pair_id": "fda_0053", "track_b": { "text": "# Levothyroxine (Synthroid) for Hypothyroidism\n\n**Status: Currently approved and safe.**\n\nLevothyroxine remains FDA-approved for hypothyroidism replacement therapy in adults and pediatric patients (including neonates) across all three categories you mentioned: primary thyroidal, secondary pituitary, and tertiary hypothalamic hypothyroidism. There has been no FDA regulatory action withdrawing or significantly restricting this indication\u2014it remains a standard, first-line treatment with a well-established safety profile when properly dosed and monitored.", "input_tokens": 127, "output_tokens": 128 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly states that levothyrox" } }, { "pair_id": "fda_0054", "track_b": { "text": "# FDA Status Answer\n\nWithout knowing the specific drug name from your question, I cannot provide a definitive answer about its current approval status. However, if you're referring to a classic antihypertensive tablet class (such as thiazide diuretics, ACE inhibitors, or beta-blockers), most remain FDA-approved and safe for hypertension treatment, often used as monotherapy or in combination.\n\n**Please specify the drug name** so I can confirm its current FDA status and any regulatory changes that may have occurred.", "input_tokens": 114, "output_tokens": 115 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer fails to identify the drug as cl" } }, { "pair_id": "fda_0055", "track_b": { "text": "# L-Triiodothyronine (T3) for Hypothyroidism\n\n**Current Status: Approved and Safe**\n\nL-triiodothyronine (liothyronine/Cytomel) remains FDA-approved for hypothyroidism replacement therapy across primary, secondary, and tertiary forms. However, **levothyroxine (T4) is now the preferred first-line agent** due to better pharmacokinetics, longer half-life, and more stable serum levels; T3 monotherapy is typically reserved for specific cases where T4 conversion is impaired or combination T4/T3 therapy is indicated.\n\nNo FDA withdrawal or major regulatory action has changed its approved status, though clinical practice guidelines have evolved to favor T4-based replacement.", "input_tokens": 138, "output_tokens": 177 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer states \"No FDA withdrawal or maj" } }, { "pair_id": "fda_0056", "track_b": { "text": "# Fluoroquinolone Antibacterial Status\n\nBased on your description, you're likely referring to a fluoroquinolone like **ciprofloxacin, levofloxacin, or moxifloxacin**. These drugs remain **FDA-approved and currently marketed** for bacterial infections in adults.\n\nHowever, the FDA has significantly **restricted their use** through multiple safety warnings and label updates since the 2000s, limiting them to cases where no suitable alternatives exist, due to serious adverse effects (tendon rupture, peripheral neuropathy, QT prolongation, and others). They're no longer first-line agents for many infections they once treated routinely.\n\n*Note: Your question appears incomplete (\"in the con?\"). If you can specify the exact drug name or indication, I can provide more precise information.*", "input_tokens": 123, "output_tokens": 184 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer states moxifloxacin \"remains FDA" } }, { "pair_id": "fda_0057", "track_b": { "text": "# FDA Status of Delayed-Release Bisphosphonate for Postmenopausal Osteoporosis\n\nBased on your description, you're likely referring to **delayed-release risedronate (Atelvia)**, which remains **currently FDA-approved and safe** for postmenopausal osteoporosis treatment.\n\nHowever, bisphosphonates as a class carry important safety considerations: the FDA has issued warnings regarding **osteonecrosis of the jaw (ONJ)**, **atypical femur fractures**, and **esophageal cancer risk** with long-term use. Current guidance recommends periodic reassessment of continued need, particularly beyond 5 years of therapy. The drug itself hasn't been withdrawn, but prescribing practices have evolved to reflect these risks.", "input_tokens": 131, "output_tokens": 177 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer states the drug \"remains **curre" } }, { "pair_id": "fda_0058", "track_b": { "text": "# Topical Antifungal Status\n\nBased on your description, you're referring to **topical antifungal medications** (likely tolnaftate, miconazole, or similar OTC agents) for treating dermatophyte infections.\n\n**Current Status:** These medications remain **FDA-approved and safe** for the indicated uses (tinea pedis, tinea cruris, tinea corporis) when used as directed. No major regulatory action has withdrawn approval for these standard indications.\n\n**Note:** Always verify the specific drug name and formulation, as individual products may have different regulatory histories or labeling changes.", "input_tokens": 137, "output_tokens": 138 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly states that topical an" } }, { "pair_id": "fda_0059", "track_b": { "text": "# Atomoxetine (Strattera) - ADHD Treatment\n\n**Current Status: Still FDA-approved and safe for ADHD treatment.**\n\nAtomoxetine, a selective norepinephrine reuptake inhibitor capsule, remains approved by the FDA for ADHD in children, adolescents, and adults. No major regulatory action has withdrawn or significantly altered its approval status, though it carries standard warnings about cardiovascular monitoring and psychiatric effects common to ADHD medications.", "input_tokens": 142, "output_tokens": 109 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly states that atomoxetin" } }, { "pair_id": "fda_0060", "track_b": { "text": "I cannot provide a specific answer without knowing which drug you're referring to. Please specify the drug name and condition, and I can tell you its current FDA approval status and any regulatory actions that may have affected it.", "input_tokens": 96, "output_tokens": 46 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not address the specific dr" } }, { "pair_id": "fda_0061", "track_b": { "text": "I cannot provide a specific answer without knowing which drug you're referring to. Please specify the drug name and condition, and I can tell you its current FDA approval status and any regulatory actions that may have affected it.", "input_tokens": 96, "output_tokens": 46 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not address the specific dr" } }, { "pair_id": "fda_0062", "track_b": { "text": "# FDA Status: Acetaminophen (Tylenol)\n\n**Currently approved and safe.** Acetaminophen remains FDA-approved for all the indications you listed (headache, toothache, backache, menstrual cramps, cold symptoms, muscle aches, arthritis pain, and fever reduction).\n\nHowever, the FDA has **strengthened safety warnings** over the years, particularly regarding:\n- Maximum daily dose limits (\u22644,000 mg/day for adults)\n- Risk of liver damage, especially with alcohol use or overdose\n- Removal from combination products to prevent accidental overdose\n\nNo major regulatory action has withdrawn approval for these standard uses.", "input_tokens": 124, "output_tokens": 152 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer discusses acetaminophen (Tylenol" } }, { "pair_id": "fda_0063", "track_b": { "text": "# FDA Status of Corticosteroid Topical Formulations\n\nThese topical corticosteroid formulations (likely **clobetasol propionate** or similar potent corticosteroids at the specified strengths) remain **currently approved and safe** for treating inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.\n\nHowever, the FDA has issued important **safety labeling updates** requiring warnings about potential systemic absorption, HPA axis suppression, and Cushing's syndrome, particularly with potent formulations and prolonged use. Current guidance emphasizes using the lowest effective potency for the shortest duration and avoiding occlusive dressings unless directed by a physician.", "input_tokens": 136, "output_tokens": 154 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer states the formulations \"remain " } }, { "pair_id": "fda_0064", "track_b": { "text": "# TIKOSYN (dofetilide) - Current FDA Status\n\n**TIKOSYN remains FDA-approved and currently marketed** for maintenance of normal sinus rhythm and delay of atrial fibrillation/atrial flutter recurrence. No FDA regulatory action has withdrawn or significantly altered this indication.\n\nHowever, the drug carries **significant safety requirements**: it requires careful patient selection, baseline and periodic QTc interval monitoring, renal function assessment, and dose adjustments to minimize the risk of torsades de pointes (a serious arrhythmia). Prescribers must be certified through a Risk Evaluation and Mitigation Strategy (REMS) program.", "input_tokens": 132, "output_tokens": 147 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer states \"TIKOSYN remains FDA-appr" } }, { "pair_id": "fda_0065", "track_b": { "text": "# FDA Status: Mineral Sunscreen Powder\n\nThis appears to describe a **cosmetic sunscreen product** (mineral powder with SPF 46 claim). In the U.S., sunscreens are regulated as **over-the-counter drugs**, not cosmetics.\n\n**Current Status:** Most mineral sunscreen actives (zinc oxide, titanium dioxide) remain FDA-approved and safe. However, the FDA issued a **2019 proposed rule** questioning the safety of several sunscreen ingredients and requesting additional data\u2014this rulemaking is still **pending** and has not been finalized.\n\n**Bottom line:** Mineral sunscreen powders with zinc oxide/titanium dioxide are still widely available and considered safe for use, but the regulatory landscape remains in flux pending the FDA's final sunscreen monograph update.", "input_tokens": 112, "output_tokens": 177 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\nThe answer discusses general sunscreen regulatory status and a pendin" } }, { "pair_id": "fda_0066", "track_b": { "text": "# FDA Status: Mineral Sunscreen Powder\n\nThis appears to describe a **cosmetic sunscreen product** (mineral powder with SPF 46). Such products are regulated as **over-the-counter (OTC) drugs** by the FDA under the sunscreen monograph.\n\n**Current Status:** Mineral sunscreens containing zinc oxide and/or titanium dioxide remain **approved and safe** for OTC use. However, the FDA has not finalized updates to the sunscreen monograph since 2019, and some ingredients (like certain UV filters) have faced ongoing safety reviews. The product would need to comply with current OTC sunscreen regulations to be legally marketed.\n\n**Recommendation:** Check the specific product's ingredient list against current FDA OTC sunscreen monograph requirements to confirm compliance.", "input_tokens": 112, "output_tokens": 173 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\nThe answer is completely off-topic and irrelevant to the drug in ques" } }, { "pair_id": "fda_0067", "track_b": { "text": "# FDA Status: Benzodiazepines for Anxiety/Panic\n\nBased on your description, you're likely referring to **benzodiazepines** (such as alprazolam, lorazepam, or clonazepam).\n\n**Current Status:** These drugs remain FDA-approved for acute treatment of GAD and panic disorder in adults. However, the FDA has strengthened warnings about risks of dependence, abuse, and serious adverse effects (respiratory depression, especially when combined with opioids). Current guidance emphasizes these should be used at the lowest effective dose for the shortest duration possible, with preference for SSRIs/SNRIs as first-line treatments for these conditions.\n\n**No approval has been withdrawn**, but prescribing practices have become more cautious due to the opioid crisis and documented risks.", "input_tokens": 125, "output_tokens": 181 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer accurately reflects the current " } }, { "pair_id": "fda_0068", "track_b": { "text": "# Venlafaxine Extended-Release (Effexor XR)\n\nBased on your description, this appears to be **venlafaxine extended-release (Effexor XR)**, which remains **currently FDA-approved and safe** for these indications.\n\nThe drug is still approved for major depressive disorder in adults and generalized anxiety disorder in both adults and children 7 years and older. No FDA regulatory action has withdrawn or significantly altered these approvals, though the drug carries standard warnings (including black box warnings for increased suicidal thoughts in pediatric patients, particularly early in treatment).", "input_tokens": 122, "output_tokens": 134 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer discusses venlafaxine (Effexor X" } }, { "pair_id": "fda_0069", "track_b": { "text": "# FDA Status: Homeopathic Cold/Sinus Products\n\nThe FDA has **not formally approved** these homeopathic products for the stated indications. Homeopathic remedies operate under a different regulatory framework (the Homeopathic Pharmacopeia of the United States) and are not evaluated by the FDA for safety and efficacy like conventional drugs.\n\nIn 2021-2023, the FDA issued warning letters to several homeopathic manufacturers for making unsubstantiated disease claims, but products remain on the market with disclaimers that claims are \"not accepted medical evidence.\" The regulatory status remains unchanged\u2014they're permitted to be sold but cannot make FDA-evaluated medical claims.", "input_tokens": 126, "output_tokens": 155 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\nThe answer is about homeopathic cold/sinus products, not pramipexole " } }, { "pair_id": "fda_0070", "track_b": { "text": "# Fluorescein for Tear Break-Up Time Testing\n\n**Status: Still approved and safe for this indication.**\n\nFluorescein sodium ophthalmic solution remains FDA-approved and is the standard diagnostic agent for measuring fluorescein break-up time (FBUT) to assess tear film stability and diagnose dry eye disease. No FDA regulatory action has withdrawn or changed its approval for this well-established clinical use.", "input_tokens": 104, "output_tokens": 93 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly states that fluorescei" } }, { "pair_id": "fda_0071", "track_b": { "text": "# FDA Status: Topical Antibiotic Ointments for Minor Wounds\n\nYes, topical antibiotic ointments (such as those containing bacitracin, neomycin, and polymyxin B) remain **currently approved and safe** by the FDA for first aid use on minor cuts, scrapes, and burns to help prevent infection.\n\nHowever, the FDA has issued warnings about **neomycin** specifically, noting increased reports of allergic contact dermatitis. Products containing only bacitracin and polymyxin B (without neomycin) are generally preferred to minimize this risk.", "input_tokens": 96, "output_tokens": 139 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer states the products are \"current" } }, { "pair_id": "fda_0072", "track_b": { "text": "# NP Thyroid\u00ae - Current FDA Status\n\n**NP Thyroid\u00ae remains FDA-approved and available** for thyroid hormone replacement therapy in hypothyroidism. However, the product has faced significant regulatory scrutiny:\n\n- **2009 FDA Warning Letter**: The manufacturer received a warning letter regarding manufacturing and quality control deficiencies.\n- **Current Status**: The product is still marketed and approved, but practitioners should be aware of historical quality concerns. The FDA has not withdrawn approval, though some patients and providers have switched to other thyroid products due to these historical issues.\n\nFor the most current safety information, consult the FDA's Orange Book or MedWatch database.", "input_tokens": 130, "output_tokens": 147 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer states \"NP Thyroid\u00ae remains FDA-" } }, { "pair_id": "fda_0073", "track_b": { "text": "# Ipratropium Bromide Nasal Solution 0.06% - Current Status\n\n**Yes, this indication remains currently approved and safe.** Ipratropium bromide nasal spray 0.06% is still FDA-approved for symptomatic relief of rhinorrhea (runny nose) associated with the common cold and seasonal allergies. There have been no FDA regulatory actions withdrawing or significantly changing the safety status of this indication.", "input_tokens": 132, "output_tokens": 100 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n1. **currency_correct=0**: The answer discusses ipratropium bromide n" } }, { "pair_id": "fda_0074", "track_b": { "text": "# Lidocaine Injection for Local/Regional Anesthesia\n\nLidocaine injection remains **currently approved and safe** by the FDA for local or regional anesthesia in adults for surgery, dental, and oral procedures. It is one of the most widely used local anesthetics in clinical practice with a well-established safety profile when used appropriately at recommended doses and with proper injection techniques.\n\nNo major FDA regulatory action has withdrawn or significantly altered its approval status for these indications.", "input_tokens": 121, "output_tokens": 106 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly states that lidocaine " } }, { "pair_id": "fda_0075", "track_b": { "text": "I cannot provide a specific answer without knowing which drug you're referring to. Please specify the drug name and condition, and I can tell you its current FDA approval status and any regulatory actions that may have affected it.", "input_tokens": 96, "output_tokens": 46 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not address the specific dr" } }, { "pair_id": "fda_0076", "track_b": { "text": "# Cinacalcet (Sensipar) for CKD Stages 3-4\n\n**Current Status: Still FDA-approved, but with important restrictions.**\n\nCinacalcet remains approved for secondary hyperparathyroidism in CKD patients; however, the FDA significantly **narrowed its indication in 2012** due to safety concerns. It is now indicated primarily for **CKD Stage 5 (dialysis patients)** and Stage 3-4 patients only in specific circumstances. The drug carries a **black box warning** for hypocalcemia risk and increased cardiovascular mortality in some patient populations. Current use requires careful patient selection and monitoring of serum calcium levels.", "input_tokens": 131, "output_tokens": 156 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Explanation:**\n- The answer discusses **cinacalcet (Sensipar)**, not **paricalcit" } }, { "pair_id": "fda_0077", "track_b": { "text": "# FDA Status: Imatinib (Gleevec)\n\nImatinib capsules remain **currently approved and safe** by the FDA for treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in adults and pediatric patients \u22651 year of age. There has been no FDA withdrawal or safety-based regulatory action that has changed its approved status since its initial approval in 2001.", "input_tokens": 123, "output_tokens": 102 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n1. **currency_correct=0**: The answer discusses imatinib (Gleevec), n" } }, { "pair_id": "fda_0078", "track_b": { "text": "I cannot provide a specific answer without knowing which drug you're referring to. Please specify the drug name and condition, and I can tell you its current FDA approval status and any regulatory actions that may have affected it.", "input_tokens": 96, "output_tokens": 46 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not address the actual drug" } }, { "pair_id": "fda_0079", "track_b": { "text": "# Sunscreen Safety Status\n\nSunscreens remain FDA-approved and safe when used as directed. However, the FDA has taken regulatory action: in 2019, it determined that only **two active ingredients are generally recognized as safe and effective (GRASE)** \u2014 **zinc oxide and titanium dioxide**. Many other previously used sunscreen ingredients (like oxybenzone and avobenzone) are now considered not GRASE and require further safety data, effectively removing them from over-the-counter products.", "input_tokens": 120, "output_tokens": 113 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer discusses sunscreen ingredients " } }, { "pair_id": "fda_0080", "track_b": { "text": "# ZITUVIMET Status\n\nZITUVIMET is a combination of sitagliptin and **metformin HCl** (the biguanide). This combination product remains **currently FDA-approved and safe** for use as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes. There has been no FDA regulatory action withdrawing or changing its approval status.", "input_tokens": 147, "output_tokens": 90 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly states that ZITUVIMET " } }, { "pair_id": "fda_0081", "track_b": { "text": "# FDA Status: Sublingual Pellet Formulation\n\nBased on the administration instructions you've described (sublingual pellets in a tube with a rotating cap), this appears to reference a **homeopathic or alternative medicine product** rather than an FDA-approved pharmaceutical drug.\n\n**Current Status:** If this is a homeopathic remedy, it falls under FDA's homeopathic drug regulations (21 CFR Part 1700), which allow marketing without pre-approval. However, **homeopathic products are not FDA-approved in the traditional sense** and lack rigorous efficacy/safety evidence. The FDA has increased scrutiny of homeopathic products in recent years.\n\n**To give you a definitive answer, I would need:** the specific drug name, manufacturer, or active ingredient listed on the product label.", "input_tokens": 125, "output_tokens": 180 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not mention any FDA recall " } }, { "pair_id": "fda_0082", "track_b": { "text": "# NP Thyroid\u00ae - Current FDA Status\n\n**NP Thyroid\u00ae remains FDA-approved and available** for thyroid hormone replacement therapy in hypothyroidism. However, the product has faced significant regulatory scrutiny:\n\n- **2009 FDA Warning Letter**: The manufacturer received a warning letter regarding manufacturing and quality control deficiencies.\n- **Current Status**: The product is still marketed and approved, but practitioners should be aware of historical quality concerns. The FDA has not withdrawn approval, though some patients and providers have switched to other thyroid products due to these historical issues.\n\nFor the specific indication you mentioned (replacement therapy in hypothyroidism), it remains an approved use, though levothyroxine monoproducts are generally considered first-line therapy.", "input_tokens": 130, "output_tokens": 166 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly identifies that NP Thy" } }, { "pair_id": "fda_0083", "track_b": { "text": "# Fulvestrant (Faslodex)\n\nYes, **fulvestrant injection remains FDA-approved and safe** for HR-positive, HER2-negative breast cancer. It was initially approved in 2002 and continues to be used as an endocrine therapy option, often in combination with CDK4/6 inhibitors or as monotherapy for advanced disease.\n\nThere have been no FDA withdrawals or safety-based regulatory actions that have changed its approved status for this indication.", "input_tokens": 128, "output_tokens": 109 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer states \"There have been no FDA w" } }, { "pair_id": "fda_0084", "track_b": { "text": "I'd be happy to help, but your question appears incomplete. You've described a generic SSRI for major depressive disorder but haven't specified which drug you're asking about, nor have you completed the question about what the tablets are indicated for.\n\nCould you please clarify:\n1. Which specific SSRI drug you're asking about (e.g., sertraline, fluoxetine, paroxetine, etc.)?\n2. What specific indication or use you want me to verify for current FDA approval status?\n\nOnce you provide these details, I can give you accurate information about its current approval status and any regulatory changes.", "input_tokens": 127, "output_tokens": 138 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not address trazodone's FDA" } }, { "pair_id": "fda_0085", "track_b": { "text": "# FDA Status: Benzodiazepines for Anxiety\n\nBased on your description, you're referring to **benzodiazepines** (likely diazepam or similar agents). These medications **remain FDA-approved** for anxiety disorders and short-term anxiety relief.\n\nHowever, the FDA has strengthened safety warnings over time, particularly regarding:\n- Risk of dependence and abuse\n- Respiratory depression (especially with opioids)\n- Cognitive impairment and fall risk in elderly patients\n\nCurrent guidance emphasizes these should be used at the **lowest effective dose for the shortest duration possible**, with preference for SSRIs or other alternatives for long-term anxiety management. The safety profile hasn't changed fundamentally, but prescribing practices have become more cautious.", "input_tokens": 117, "output_tokens": 169 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly states that diazepam/b" } }, { "pair_id": "fda_0086", "track_b": { "text": "# FDA Status: Nasal Spray Antihistamine for Allergic Rhinitis\n\nBased on your description, you're likely referring to **azelastine nasal spray** or a similar intranasal antihistamine.\n\n**Current Status:** These medications remain **FDA-approved and safe** for treating seasonal allergic rhinitis in adults and children 5 years and older. No major FDA regulatory action has withdrawn or significantly changed their approval status in recent years.\n\n**Note:** Your question appears incomplete (ends with \"for the treatment of t?\"). If you can specify the exact drug name or complete indication, I can provide more precise information about any specific regulatory changes.", "input_tokens": 124, "output_tokens": 146 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer states \"No major FDA regulatory " } }, { "pair_id": "fda_0087", "track_b": { "text": "I don't have any information about a drug called \"AHZANTIVE\" in my knowledge base. This appears to be either a very recently approved medication (given the 2024 approval date mentioned), a fictional drug name, or possibly a misspelling.\n\nTo get accurate, current information about this drug's FDA approval status and safety, I recommend checking the FDA's official drug database (Drugs@FDA) or consulting the current prescribing information directly from the manufacturer or FDA website.", "input_tokens": 131, "output_tokens": 106 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not address aflibercept's a" } }, { "pair_id": "fda_0088", "track_b": { "text": "# Naproxen Approval Status\n\nNaproxen tablets and naproxen sodium tablets **remain currently FDA-approved** for the relief of signs and symptoms of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. However, the indication appears incomplete in your question (ending with \"Polya?\"), so I cannot confirm the full list.\n\n**Important safety note:** The FDA has strengthened warnings about cardiovascular and gastrointestinal risks with NSAIDs like naproxen, particularly with long-term use, but the drug has not been withdrawn or had its core indications removed.", "input_tokens": 137, "output_tokens": 144 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n1. **currency_correct=0**: The answer fails to address the actual dru" } }, { "pair_id": "fda_0089", "track_b": { "text": "I'd be happy to help, but your question appears incomplete. You've started describing a drug indicated for hypertension that can be used alone or with thiazide diuretics, but the question cuts off at \"this drug capsules USP are?\"\n\nCould you please:\n1. Specify the drug name (e.g., verapamil, diltiazem, nifedipine, etc.)\n2. Complete your question about its current FDA approval status\n\nOnce you provide the specific drug name and complete question, I can give you accurate information about its current regulatory status.", "input_tokens": 135, "output_tokens": 128 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not address the drug (ramip" } }, { "pair_id": "fda_0090", "track_b": { "text": "# Nitroglycerin Sublingual Tablets\n\n**Status: Still approved and safe for current use.**\n\nNitroglycerin sublingual tablets remain FDA-approved and are the standard of care for acute angina relief. No regulatory action has withdrawn or significantly changed their approval status. They continue to be recommended as first-line therapy for acute anginal episodes and are listed in current clinical guidelines (ACC/AHA) for this indication.", "input_tokens": 124, "output_tokens": 97 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: Nitroglycerin sublingual tablets have NOT b" } }, { "pair_id": "fda_0091", "track_b": { "text": "# Isotretinoin (Accutane) for Severe Recalcitrant Nodular Acne\n\n**Yes, isotretinoin remains FDA-approved and indicated for this condition.** It is the only drug that can potentially cure severe recalcitrant nodular acne and remains the gold standard treatment for this indication.\n\nHowever, its use is **highly regulated** under the **iPLEDGE program** (established 2002), which requires strict monitoring due to severe teratogenicity and other serious adverse effects. Prescribers, patients, and pharmacies must be registered, and patients must meet specific criteria including documented treatment failures with other therapies.", "input_tokens": 134, "output_tokens": 151 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly states that isotretino" } }, { "pair_id": "fda_0092", "track_b": { "text": "I cannot provide a specific answer without knowing which drug you're referring to. Please specify the drug name and condition, and I can tell you its current FDA approval status and any regulatory actions that may have affected it.", "input_tokens": 96, "output_tokens": 46 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not mention the recall/enfo" } }, { "pair_id": "fda_0093", "track_b": { "text": "# FDA Status: Benzodiazepines for Anxiety\n\nBenzodiazepine tablets (such as diazepam, alprazolam, lorazepam) remain **FDA-approved** for anxiety disorders and short-term anxiety relief. However, the FDA has significantly strengthened safety warnings over the past decade, including black box warnings about risks of dependence, abuse, and respiratory depression\u2014especially when combined with opioids.\n\nCurrent guidance emphasizes these drugs should be used at the lowest effective dose for the shortest duration possible due to addiction and withdrawal risks, making them less favored as first-line treatment compared to SSRIs or other alternatives.", "input_tokens": 116, "output_tokens": 145 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n1. **currency_correct=0**: The answer discusses benzodiazepines (diaz" } }, { "pair_id": "fda_0094", "track_b": { "text": "# FDA Status: Meprobamate\n\nBased on the indication you've described, this refers to **meprobamate**, a carbamate anxiolytic from the 1950s-60s era.\n\n**Current Status:** Meprobamate remains FDA-approved but is **rarely used** in modern practice. While not formally withdrawn, it has been largely superseded by benzodiazepines and SSRIs due to:\n- Higher abuse/dependence potential\n- Narrow therapeutic window\n- Safety concerns (overdose toxicity, withdrawal seizures)\n- Better alternatives available\n\nThe drug is still technically approved for anxiety but carries significant regulatory cautions and is considered obsolete by contemporary psychiatric standards. Most clinicians no longer prescribe it.", "input_tokens": 120, "output_tokens": 164 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\nThe answer is about **meprobamate**, not hydroxyzine pamoate. This is" } }, { "pair_id": "fda_0095", "track_b": { "text": "I cannot provide a specific answer without knowing which drug you're referring to. Please specify the drug name and condition, and I can tell you its current FDA approval status and any regulatory actions that may have affected it.", "input_tokens": 96, "output_tokens": 46 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not mention any recall or F" } }, { "pair_id": "fda_0096", "track_b": { "text": "# Rifampin Status\n\nRifampin remains **currently approved and safe** by the FDA for both tuberculosis and meningococcal carrier state treatment. However, the concern you're referencing about resistance development is clinically significant: rifampin should **never be used as monotherapy** due to rapid emergence of resistant organisms. It must always be combined with other antimicrobial agents to prevent the small population of naturally resistant cells from proliferating and causing treatment failure.", "input_tokens": 118, "output_tokens": 104 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly states that rifampin \"" } }, { "pair_id": "fda_0097", "track_b": { "text": "I cannot provide a specific answer without knowing which drug you're referring to. Please specify the drug name and condition, and I can tell you its current FDA approval status and any regulatory actions that may have affected it.", "input_tokens": 96, "output_tokens": 46 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 0, "judge_text": "currency_correct=0 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=0**: The answer does not address the specific dr" } }, { "pair_id": "fda_0098", "track_b": { "text": "# Isosorbide Dinitrate Extended-Release\n\nBased on your description, you're asking about **isosorbide dinitrate extended-release** for chronic angina.\n\n**Current Status: Still Approved and Safe**\n\nIsosorbide dinitrate extended-release tablets remain FDA-approved for chronic angina treatment and are considered safe when used as directed. The drug is commonly used in combination with beta-blockers, nitrates, and calcium channel blockers as you mentioned. No major FDA regulatory action has withdrawn or significantly altered its approval status for this indication.", "input_tokens": 123, "output_tokens": 127 }, "track_b_score": { "currency_correct": 0, "anchor_leak": 1, "judge_text": "currency_correct=0 anchor_leak=1\n\n**Reasoning:**\n\n1. **currency_correct=0**: The answer states the drug is \"Still Appro" } }, { "pair_id": "fda_0099", "track_b": { "text": "# Motion Sickness Medications - Current FDA Status\n\nThe indication for preventing and treating nausea, vomiting, and dizziness associated with motion sickness remains **currently approved and safe** for several FDA-approved medications, including:\n\n- **Dimenhydrinate** (Dramamine)\n- **Meclizine** (Bonine, Antivert)\n- **Promethazine** (Phenergan)\n- **Scopolamine** (transdermal patch)\n\nThese drugs continue to be available over-the-counter or by prescription with no major FDA regulatory action withdrawing these indications. However, healthcare providers should always be consulted for individual patient suitability, as side effects (drowsiness, anticholinergic effects) and contraindications vary by drug and patient.", "input_tokens": 114, "output_tokens": 184 }, "track_b_score": { "currency_correct": 1, "anchor_leak": 0, "judge_text": "currency_correct=1 anchor_leak=0\n\n**Reasoning:**\n\n- **currency_correct=1**: The answer correctly states that meclizine " } } ] }